PURPOSE: To determine the incidence and frequency of the Bcl-2/IgH rearrangement in the peripheral blood of normal individuals to define the potential complication this may pose for the molecular monitoring of disease in patients with follicular lymphoma (FL). MATERIALS AND METHODS: The incidence and frequency of the major breakpoint cluster region rearrangement in DNA extracted from peripheral blood or lymphoblastoid cell lines from 481 normal individuals was determined using a TaqMan real-time polymerase chain reaction assay (PE Applied Biosystems, Foster City, CA). RESULTS: Twenty three percent of samples were positive for the Bcl-2/IgH rearrangement, with approximately 3% of these at levels of more than 1 in 10(4) cells. CONCLUSION: The presence of circulating Bcl-2/IgH+ cells, other than those derived from the malignant clone, could confound the detection and quantitation of minimal residual disease in patients with FL, particularly at low levels of tumor burden.
PURPOSE: To determine the incidence and frequency of the Bcl-2/IgH rearrangement in the peripheral blood of normal individuals to define the potential complication this may pose for the molecular monitoring of disease in patients with follicular lymphoma (FL). MATERIALS AND METHODS: The incidence and frequency of the major breakpoint cluster region rearrangement in DNA extracted from peripheral blood or lymphoblastoid cell lines from 481 normal individuals was determined using a TaqMan real-time polymerase chain reaction assay (PE Applied Biosystems, Foster City, CA). RESULTS: Twenty three percent of samples were positive for the Bcl-2/IgH rearrangement, with approximately 3% of these at levels of more than 1 in 10(4) cells. CONCLUSION: The presence of circulating Bcl-2/IgH+ cells, other than those derived from the malignant clone, could confound the detection and quantitation of minimal residual disease in patients with FL, particularly at low levels of tumor burden.
Authors: Sharon L Barrans; Paul A S Evans; Sheila J M O'Connor; Roger G Owen; Gareth J Morgan; Andrew S Jack Journal: J Mol Diagn Date: 2003-08 Impact factor: 5.568
Authors: Dilini N Thilakaratne; Monique N Mayer; Valerie S MacDonald; Marion L Jackson; Brenda R Trask; Beverly A Kidney Journal: Can Vet J Date: 2010-01 Impact factor: 1.008
Authors: Gerardo Colon-Otero; Scott A Van Wier; Greg J Ahmann; Esteban Braggio; Monica L Albertie; Jennifer A Weis; Sikander Ailawadhi; James R Cerhan; Prakash Vishnu; Matthew S Jorgensen; James M Foran; Colleen S Thomas; Rafael Fonseca Journal: Ann Hematol Date: 2016-10-12 Impact factor: 3.673
Authors: Kacey L Sachen; Michael J Strohman; Jonathan Singletary; Ash A Alizadeh; Nicole H Kattah; Chen Lossos; Elizabeth D Mellins; Shoshana Levy; Ronald Levy Journal: Blood Date: 2012-09-28 Impact factor: 22.113
Authors: Armin G Jegalian; Franziska C Eberle; Svetlana D Pack; Mariya Mirvis; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe Journal: Blood Date: 2011-07-18 Impact factor: 22.113
Authors: Carsten Hirt; Kerstin Weitmann; Frank Schüler; Thomas Kiefer; Charles S Rabkin; Wolfgang Hoffmann; Gottfried Dölken Journal: Leuk Lymphoma Date: 2013-05-07
Authors: María Sol Brassesco; Danilo Jordão Xavier; Marjori Leiva Camparoto; Ana Paula Montaldi; Paulo Roberto D'Auria Vieira de Godoy; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Elza Tiemi Sakamoto-Hojo Journal: J Biomed Biotechnol Date: 2010-08-31
Authors: A A Lane; O Odejide; N Kopp; S Kim; A Yoda; R Erlich; N Wagle; G A Abel; S J Rodig; J H Antin; D M Weinstock Journal: Leukemia Date: 2013-02-01 Impact factor: 11.528